Ono 6240

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525788

CAS#: 99659-62-8

Description: Ono 6240 is a platelet-activating factor antagonist. Studies suggest that Ono 6240 prevented airway eosinophilia by inhibiting production of IL-5 and IL-2 (Interleukin Levels). Results suggested that ONO-6240 may be of value in treating human asthmatic patients.


Chemical Structure

img
Ono 6240
CAS# 99659-62-8

Theoretical Analysis

MedKoo Cat#: 525788
Name: Ono 6240
CAS#: 99659-62-8
Chemical Formula: C32H63NO6S2
Exact Mass: 621.4097
Molecular Weight: 621.9757
Elemental Analysis: C, 61.79; H, 10.21; N, 2.25; O, 15.43; S, 10.31

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ono6240; Ono-6240; Ono 6240

IUPAC/Chemical Name: 3-(7-(2-ethoxy-3-(hexadecyloxy)propoxy)heptyl)thiazol-3-ium methanesulfonate

InChi Key: QMWHFMOIMBFWSK-UHFFFAOYSA-M

InChi Code: InChI=1S/C31H60NO3S.CH4O3S/c1-3-5-6-7-8-9-10-11-12-13-14-15-18-21-25-33-28-31(35-4-2)29-34-26-22-19-16-17-20-23-32-24-27-36-30-32;1-5(2,3)4/h24,27,30-31H,3-23,25-26,28-29H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1

SMILES Code: CCCCCCCCCCCCCCCCOCC(OCC)COCCCCCCC[N+]1=CSC=C1.CS(=O)([O-])=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 621.9757 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shi H, Xu H, Liang G. [Effects of a platelet-activating factor antagonist ONO-6240 on antigen induced eosinophil infiltration into the airways]. Zhonghua Nei Ke Za Zhi. 1995 Nov;34(11):753-6. Chinese. PubMed PMID: 8731847.
2: Ando M, Suginami H, Matsuura S. Pregnancy suppression by a platelet activating factor antagonist, ONO-6240, in mice. Asia Oceania J Obstet Gynaecol. 1990 Jun;16(2):169-74. PubMed PMID: 2378595.
3: Toyofuku T, Kubo K, Kobayashi T, Kusama S. Effects of ONO-6240, a platelet-activating factor antagonist, on endotoxin shock in unanesthetized sheep. Prostaglandins. 1986 Feb;31(2):271-81. PubMed PMID: 3754344.
4: Hwang SB, Lam MH. Species difference in the specific receptors of platelet activating factor. Biochem Pharmacol. 1986 Dec 15;35(24):4511-8. PubMed PMID: 3024653.
5: Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8. PubMed PMID: 3612533.
6: Hsueh W, Gonzalez-Crussi F, Arroyave JL, Anderson RC, Lee ML, Houlihan WJ. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. Eur J Pharmacol. 1986 Apr 9;123(1):79-83. PubMed PMID: 3754817.
7: Hakugawa J, Bae SJ, Vinuesa MA, Tanaka Y, Katayama I. [The inhibitory effect of LTB4 antagonist on eosinophil infiltration in cutaneous and gut late phase response in BALB/C mice sensitized with ovalubumin (OVA)]. Arerugi. 1997 Jan;46(1):42-8. Japanese. PubMed PMID: 9078611.
8: Hwang SB. Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes. J Biol Chem. 1988 Mar 5;263(7):3225-33. PubMed PMID: 2830276.
9: Mikami T, Fukushi K, Ishitani M, Ishitani K, Suzuki S, Suzuki M. Induction of platelet-activating factor in mice by intravenous administration of a neutral fraction of bakers' yeast mannan. Lipids. 1991 Dec;26(12):1404-7. PubMed PMID: 1819741.
10: Tokumura A, Yoshida J, Maruyama T, Fukuzawa K, Tsukatani H. Platelet aggregation induced by ether-linked phospholipids. 1. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. Thromb Res. 1987 Apr 1;46(1):51-63. PubMed PMID: 3647677.
11: Hwang SB. Specific receptor sites for platelet activating factor on rat liver plasma membranes. Arch Biochem Biophys. 1987 Sep;257(2):339-44. PubMed PMID: 2821908.
12: Hirafuji M, Shinoda H. Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet-activating factor in vitro. Br J Pharmacol. 1991 Jun;103(2):1333-8. PubMed PMID: 1884095; PubMed Central PMCID: PMC1908373.
13: Paulson SK, Wolf JL, Novotney-Barry A, Cox CP. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor. Proc Soc Exp Biol Med. 1990 Nov;195(2):247-54. PubMed PMID: 2172997.
14: Redl H, Vogl C, Schiesser A, Paul E, Thurnher M, Bahrami S, Schlag G. Effect of the PAF antagonist BN 52021 in ovine endotoxin shock. J Lipid Mediat. 1990;2 Suppl:S195-201. PubMed PMID: 2133282.
15: Tokumura A, Yoshida J, Okasaka N, Fukuzawa K, Tsukatani H. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. Thromb Res. 1987 Apr 1;46(1):153-61. PubMed PMID: 3590110.
16: Tokumura A, Tsukatani H. [Antagonists of platelet activating factor]. Seikagaku. 1985 Dec;57(12):1618-23. Review. Japanese. PubMed PMID: 3009656.
17: Ohtsuka T, Hiura M, Ozawa M, Okamura N, Ishibashi S. Synergism between platelet-activating factor and diacylglycerol in the induction of superoxide anion production in guinea pig polymorphonuclear leukocytes. Arch Biochem Biophys. 1990 May 15;279(1):21-4. PubMed PMID: 2159756.
18: Hirafuji M, Shinoda H. Antagonism of platelet-activating factor-induced increase in cytosolic free calcium concentration in human endothelial cells. Jpn J Pharmacol. 1992 Mar;58(3):231-41. PubMed PMID: 1513073.
19: Noguchi K, Morita I, Murota S. The detection of platelet-activating factor in inflamed human gingival tissue. Arch Oral Biol. 1989;34(1):37-41. PubMed PMID: 2783040.